Suppr超能文献

细胞内活性氧的下调减弱了爱泼斯坦-巴尔病毒阳性NK/T细胞淋巴瘤中P-糖蛋白相关的化疗耐药性。

Down-regulation of intracellular reactive oxygen species attenuates P-glycoprotein-associated chemoresistance in Epstein-Barr virus-positive NK/T-cell lymphoma.

作者信息

Nam Young-Sun, Im Keon-Il, Kim Nayoun, Song Yunejin, Lee Jun-Seok, Jeon Young-Woo, Cho Seok-Goo

机构信息

Institute for Translational Research and Molecular Imaging, The Catholic University of Korea, College of Medicine Korea.

Department of Biomedicine and Health Sciences, The Catholic University of Korea, College of Medicine Korea.

出版信息

Am J Transl Res. 2019 Mar 15;11(3):1359-1373. eCollection 2019.

Abstract

Epstein-Barr virus (EBV)-positive extranodal NK/T-cell lymphoma is a rare and highly aggressive disease with a poor prognosis and strong resistance to anti-cancer drugs. Reactive oxygen species (ROS) are closely related to tumorigenesis and P-glycoprotein (P-gp) is highly expressed in various cancers. However, the exact relationship between ROS and P-gp in EBV-positive lymphoma remains unclear. In this study, we demonstrated that EBV latent infection induced intracellular ROS production and increased ROS levels triggered elevated P-gp expression, which resulted in strong resistance to existing anti-cancer drugs in EBV-positive lymphoma cell lines and in patients' tissue samples. We also verified that regulation of intracellular ROS reduced P-gp expression and function via inhibition of STAT1 phosphorylation. These results indicate that treatment with a ROS scavenger is a potential therapeutic strategy to overcome resistance to anti-cancer drugs by downregulating the expression of P-gp in EBV-positive NK/T-cell lymphoma.

摘要

爱泼斯坦-巴尔病毒(EBV)阳性结外NK/T细胞淋巴瘤是一种罕见且侵袭性很强的疾病,预后较差,对抗癌药物具有很强的耐药性。活性氧(ROS)与肿瘤发生密切相关,P-糖蛋白(P-gp)在各种癌症中高表达。然而,EBV阳性淋巴瘤中ROS与P-gp的确切关系仍不清楚。在本研究中,我们证明EBV潜伏感染诱导细胞内ROS产生,ROS水平升高触发P-gp表达增加,这导致EBV阳性淋巴瘤细胞系和患者组织样本对现有抗癌药物产生强烈耐药性。我们还证实,调节细胞内ROS可通过抑制STAT1磷酸化来降低P-gp表达和功能。这些结果表明,用ROS清除剂进行治疗是一种潜在的治疗策略,可通过下调EBV阳性NK/T细胞淋巴瘤中P-gp的表达来克服对抗癌药物的耐药性。

相似文献

7
Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma.结外NK/T细胞淋巴瘤的新型免疫治疗选择
Front Oncol. 2018 Apr 30;8:139. doi: 10.3389/fonc.2018.00139. eCollection 2018.

引用本文的文献

2
Advances and challenges of immunotherapies in NK/T cell lymphomas.NK/T细胞淋巴瘤免疫治疗的进展与挑战
iScience. 2023 Oct 12;26(11):108192. doi: 10.1016/j.isci.2023.108192. eCollection 2023 Nov 17.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验